抗结核药物性肝损伤研究进展

摘要/Abstract

摘要： 抗结核药物性肝损伤(anti-tuberculosis drug-induced liver injury, AT-DILI)是临床抗结核治疗中最常见、危害最大的不良反应。本文从AT-DILI的发生率、危险因素、分子机制和风险评估等方面阐述了AT-DILI的最新进展, 希望通过深入研究抗结核药物性肝损伤的分子机制, 给未来结核病个体化治疗和管理寻找重要突破口。

关键词: 结核, 抗结核药物性肝损伤, 分子机制

Abstract: Anti-tuberculosis drug-induced liver injury (AT-DILI) is the leading adverse drug reaction during tuberculosis treatment. This review summarizes the latest information of incidence, risk factors, mechanism and prediction associated with AT-DILI. Better understanding of the mechanisms of AT-DILI may help to the individualized treatment and effective management of tuberculosis in the future.

Key words: Tuberculosis, Anti-tuberculosis drug-induced liver injury, Mechanism

张锦欣, 陈娟娟, 彭劼. 抗结核药物性肝损伤研究进展[J]. 新发传染病电子杂志, 2019, 4(3): 173-176.

ZHANG Jin-xin, CHEN Juan-juan, PENG Jie. Research progress of Anti-tuberculosis drug-induced liver injury[J]. Electronic Journal of Emerging Infectious Diseases, 2019, 4(3): 173-176.

参考文献

[1] Kullak-Ublick GA, Andrade RJ, Merz M, et al.Drug-induced liver injury: recent advances in diagnosis and risk assessment[J]. Gut, 2017, 66(6):1154-1164.
[2] Chen Y, Ye P, Ren C, et al.Pharmacoeconomics of three Therapeutic Schemes for Anti-tuberculosis Therapy Induced Liver Injury in China[J]. Open Med (Wars), 2018, 13(1): 53-63.
[3] Luangchosiri C, Thakkinstian A, Chitphuk S, et al.A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury[J]. BMC Complement Altern Med, 2015, 15(1):334.
[4] Tweed CD, Wills GH, Crook AM, et al.Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study[J]. BMC Med, 2018, 16(1):46.
[5] Chang TE, Huang YS, Chang CH, et al.The susceptibility of anti-tuberculosis drug-induced liver injury and chronic hepatitis C infection: A systematic review and meta-analysis[J]. J Chin Med Assoc, 2018, 81(2):111-118.
[6] Chen L, Bao D, Gu L, et al.Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment[J]. BMC Infect Dis, 2018, 18(1):295.
[7] 孙勤, 肖和平. 抗结核药物所致肝损伤分子遗传机制的探讨[J]. 中华结核和呼吸杂志, 2018, 41(1):10-13.
[8] 刘奉凤, 陈耀凯. 抗结核药物性肝损伤的研究进展[J]. 重庆医学, 2014, 43(19):2512-2514.
[9] Costiniuk CT, Gosnell BI, Manzini TC, et al.Tuberculous Drug-induced Liver Injury and Treatment Re-challenge in Human Immunodeficiency Virus Co-infection[J]. J Glob Infect Dis, 2015, 7(4):151-156.
[10] Chen R, Wang J, Zhang Y, et al.Key factors of susceptibility to anti-tuberculosis drug-induced hepatotoxicity[J]. Arch Toxicol, 2015, 89(6):883-897.
[11] Zhang J, Zhu X, Li Y, et al.Correlation of CpG Island Methylation of the Cytochrome P450 2E1/2D6 Genes with Liver Injury Induced by Anti-Tuberculosis Drugs: A Nested Case-Control Study[J]. Int J Environ Res Public Health, 2016, 13(8):776.
[12] Metushi I, Uetrecht J, Phillips E.Mechanism of isoniazid-induced hepatotoxicity: then and now[J]. Br J Clin Pharmacol , 2016, 81(6):1030-1036.
[13] 张俊仙, 吴雪琼. 抗结核药物所致肝损伤的分子机制[J]. 中国防痨杂志, 2014, 36(1):3-8.
[14] Wang T, Yu HT, Wang W, et al.Genetic polymorphisms of cytochrome P450 and glutathione S-transferase associated with antituberculosis drug-induced hepatotoxicity in Chinese tuberculosis patients[J]. J Int Med Res, 2010, 38(3):977-986.
[15] Chang JC, Liu EH, Lee CN, et al.UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications[J]. Int J Tuberc Lung Dis, 2012, 16(3):376-378.
[16] 乔慧捷, 周东辉, 李爽. 抗结核药物性肝损伤的危险因素及发生机制[J]. 国际流行病学传染病杂志, 2017, 44(2):131-133.
[17] Nicoletti P, Aithal GP, Bjornsson ES, et al.Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study[J]. Gastroenterology, 2017, 152(5):1078-1089.
[18] Aithal GP.Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice[J]. Liver Int, 2015, 35(7):1801-1808.
[19] Director E. Letter of support for drug-induced liver injury (DILI) biomarker[EB/OL]. European Medicines Agency, 2016, https://www.ema.europa.eu/documents/other/letter-support-drug-induced-liver-injury-dili-biomarker_en.pdf.
[20] Kuepfer L, Kerb R, Henney AM.Clinical translation in the virtual liver network[J]. CPT Pharmacometrics Syst Pharmacol, 2014, 3(7):e127.